As MP-RM-1 inhibits both ligand-dependent and -independent activation of erbB3 [43], we speculate that hMP-RM-1 might exert more potent antitumor activity than MM-121 against erbB2-overexpressing breast cancer. Here, ERBB3 is linked to breast cancer.